A case report and literature review of the pathogenetic aspects of the combined infection of Epstein-Barr virus and oral candidiasis

Authors

  • S. Nykytyuk I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
  • S. Levenets I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
  • T. Kosovska I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
  • T. Nedoshytko I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine

DOI:

https://doi.org/10.22141/2312-413x.8.5-6.2020.217962

Keywords:

children, Epstein-Barr viral infection, candidiasis

Abstract

Background. Patients with a recurrent infection that is resistant to traditional therapy are a clinical challenge in pediatrics. This recurrent pathology is often hiding another disease. In addition, timely diagnosis and suggestion of etiotropic therapy are often delayed when medical ethics have been deviated, namely, when medical history collection was dubious. The objective of this article was to present the clinical peculiarities of the Epstein-Barr virus (EBV) association with oral candidiasis. Materials and methods. The authors describe the clinical case of Epstein-Barr viral infection in a 4-year-old child. The case was detected in Ternopil region. Results. The bacterial flora of the throat and mouth was inoculated, in the throat culture, Str.viridans 103 CFU/ml, S.aureus 105 CFU/ml, Candida albicans 106 CFU/ml were isolated. Enzyme-linked immunoassay showed that EBV VCA IgM antibody index was at the level of 2.63 (more than 0.8 — a positive result). Conclusions. When infectious mononucleosis is combined with oral candidiasis, the following common symptoms are observed: prolonged fever, lymphadenopathy, and exanthema syndrome. They usually occur after administration of broad-spectrum antibacterial agents. In case of disease with symptoms such as prolonged fever, lymphadenopathy, tonsillitis, and exanthema syndrome, which are common for both oral candidiasis and infectious mononucleosis, differential diagnosis is required. There is a need to examine the microbiota of the oropharynx in patients with infectious mononucleosis to detect flora, which may lead to complicated course of the disease and diagnosis. In such case, inoculation of oropharynx microbiota is essential instrument for candidiasis diagnosis.

References

Voloha A.P. Epstein­Barr viral infection in children. Sovremennaya pediatriya. 2015. 4(68). 103­110 (in Ukrainian).

Linke­Serinsöz E., Fend F., Quintanilla­Martinez L. Human immunodeficiency virus (HIV) and Epstein­Barr virus (EBV) related lym-phomas, pathology view point. Semin. Diagn. Pathol. 2017. 34(4). 352­363.

Chan C.W., Chiang A.K.S., Chan K.H. Epstein­Barr virus­associated infectious mononucleosis in Chinese children. Pediatric Infectious Disease Journal. 2003. 22(11). 974­978.

Steinbach W.J., Roilides E., Berman D. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatric Infectious Disease Journal. 2012. 31(12). 1252­1257.

Manfredi R., Coronado O.V., Mastroianni A. Concurrent infectious mononucleosis and measles: a potentially life­threatening association sharing underlying immunodeficiency. Pediatric Infectious Disease Journal. 2003. 22(5). 470­471.

Linde A., Falk K.I. Epstein­Barr virus. In: Manual of clinical microbiology. Ninth edition. Ed. by E.J. Barron, J.H. Jorgensen, M.L. Landry et al. ASM Press, 2007. 1564­1573.

Setoh J.W.S., Ho C.K.M., Yung C.F. Epstein­Barr virus seroprevalence and force of infection in a multiethnic pediatric cohort, Singapore. Pediatric Infectious Disease Journal. 2019. 38(12). 1173­1176.

Palazzi D.L., Arrieta A., Castagnola E. Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi­national study. Pediatric Infectious Disease Journal. 2014. 33(12). 1294­1296.

Pitetti R.D., Laus S., Wadowsky R.M. Clinical eva­luation of a quantitative real time polymerase chain reaction assay for diagnosis of primary Epstein­Barr virus infection in children. Pediatric Infectious Disease Journal. 2003. 22(8). 736­739.

Kramarev S.O., Vygovskaya O.V. Chronic forms of Epstein­Barr viral infection in children: current approaches to diagnosis and treat-ment. Sovremennaya pediatriya. 2008. 2(19). 103­107 (in Ukrainian).

Martin J.M., Macias­Parra M., Mudry P. et al. Safety, efficacy, and exposure­response of voriconazole in pediatric patients with invasive aspergillosis, invasive candidiasis or esophageal candidiasis. Pediatric Infectious Disease Journal. 2017. 36(1). e1­e13.

Lorenz M.C., Bender J.A., Fink G.R. Transcriptional response of Candida albicans upon internalization by macrophages. Eukaryotic Cell. 2004. 3(5). 1076­87.

Autmizguine J., Tan S., Cohen­Wolkowiez M. et al. Antifungal susceptibility and clinical outcome in neonatal candidiasis. Pediatric In-fectious Disease Journal. 2018. 37(9). 923­929.

Fugl A., Andersen C.L. Epstein­Barr virus and its association with disease — a review of relevance to general practice. BMC Fam. Pract. 2019. 20. 62.

Dunmire S.K., Hogquist K.A., Balfour H.H. Infectious mononucleosis. Curr. Top. Microbiol. Immunol. 2015. 390. 211­40.

Sydnor E. Hospital epidemiology and infection control in acute­care settings. Clinical Microbiology Reviews. 2011. 24(1). 141­173.

Azadmanesh J., Gowen A.M., Creger P.E., Schafer N.D., Blankenship J.R. Filamentation involves two overlapping, but distinct, programs of filamentation in the pathogenic fungus Candida albicans. G3: Genes, Genomes, Genetics. 2017. 7(11). 3797­3808.

Grinstein S., Hube B., Mogavero S., Moran G., Westman J. Candida albicans hyphal expansion causes phagosomal membrane damage and luminal alkalinization. mBio. 2018. 9(5). e01226­18.

Millsop J.W., Faze L.N. Oral candidiasis. Clin. Dermatol. 2016. 34. 487­494.

Sherman R.G., Prusinski L., Joralmon R.A. Oral candidosis. Quintessence International. 2002. 33(7). 521­32.

Vila T., Sultan A.S., Montelongo­Jauregui D., Jabra­Rizk M.A. Oral candidiasis: a disease of opportunity. Journal of Fungi. 2016. 6(1). 15.

Kumamoto C.A. Candida biofilms. Current Opinion in Microbiology. 2002. 5(6). 608­11.

Ortora G.J. Microbiology: an introduction. San Francisco, CA: Pearson Benjamin Cummings, 2010. 759.

Peric M., Živkovic R., Milic Lemic A., Radunovic M., Milicic B., Arsic Arsenijevic V. The severity of denture stomatitis as related to risk factors and different Candida spp. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2018. 126. 41­47.

Singh R., Chakrabarti A. Invasive candidiasis in the Southeast­Asian region. In: Prasad R. (ed.). Candida albicans: cellular and molec-ular biology. 2nd ed. Switzerland: Springer International Publishing AG, 2017.

Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clinical Microbio­logy Reviews. 2007. 20(1). 133­63.

Roilides E., Carlesse F. et al. Safety, efficacy and pharmacokinetics of anidulafungin in patients 1 month to < 2 years of age with invasive candidiasis, including candidemia. Pediatric Infectious Disease Journal. 2020. 39(4). 305­309.

Tsekoura M., Ioannidou M., Pana Z.­D. Efficacy and safety of echinocandins for the treatment of invasive candidiasis in children: a meta­analysis. Pediatric Infectious Disease Journal. 2019. 38(1). 42­49.

Benjamin D.K. Jr, Kaufman D.A., Hope W.W. A phase 3 study of micafungin versus amphotericin B deoxycholate in infants with invasive candidiasis. Pediatric Infectious Disease Journal. 2018. 37(10). 992­998.

Kovanda L.L., Walsh T.J., Benjamin D.K. Jr. Exposure­response analysis of micafungin in neonatal candidiasis: pooled analysis of two clinical trials. Pediatric Infectious Disease Journal. 2018. 37(6). 580­585.

Roilides E., Carlesse F., Leister­Tebbe H. A prospective, open­label study to assess the safety, tolerability and efficacy of anidulafungin in the treatment of invasive candidiasis in children 2 to < 18 years of age. Pediatric Infectious Disease Journal. 2019. 38(3). 275­279.

Shkalim­Zemer V., Levi I., Fischer S. Response of symptomatic persistent chronic disseminated candidiasis to corticosteroid therapy in immunosuppressed pediatric patients: case study and review of the literature. Pediatric Infectious Disease Journal. 2018. 37(7). 686­690.

Mason K.L., Erb Downward J.R., Mason K.D., Falkowski N.R., Eaton K.A., Kao J.Y., Young V.B., Hunagle G.B. Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad­spectrum antibiotic therapy. Infect. Immun. 2012. 80. 3371­3380.

McIntyre G.T. Oral candidosis. Dent. Update. 2001. 28. 132­139.

American Academy of Pediatrics, Committee on Infectious Diseases, Committee on Nutrition. Consumption of raw or unpasteurized milk and milk products by pregnant women and children. Pediatrics. 2014. 133(1). 175­179.

Downloads

Published

2020-09-01

Issue

Vol. 8 No. 5-6 (2020)

Section

To Help the Practitioner

License

Copyright (c) 2020 ACTUAL INFECTOLOGY

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
  7. The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.